Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1345-1349

  Kariya, Shinji ^a   Ogawa, Yasuhiro ^a   Nishioka, Akihito ^a   Yoshida, Shoji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Anthracycline pretreated; Breast cancer; Cisplatin; Docetaxel

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CISPLATIN; DOCETAXEL; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADENOCARCINOMA; ADULT; ARTICLE; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SALVAGE THERAPY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PACLITAXEL; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS;

EID: 0036833836     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1345     Document Type: Article

References (24)

1. Denis JN, Correa A and Greene AE: An improved synthesis of the Taxol side chain and of RP56976. J Org Chem 55: 1957-1959, 1990.
2. Ringel I and Horwitz SB: Studies with RP56976 (Taxotere); a semisynthetic analogue of Taxol. J Natl Cancer Inst 83: 288-291, 1991.
3. Sakurai T, Tanino H, Oura S, Suzuma T, Yamamiti N, Yoshimatsu T, Sakurai T and Naito Y: Efficacy of docetaxel for recurrent breast cancer: evaluation based on chemosensitivity test and clinical response. Gan To Kagaku Ryoho 27: 423-427, 2000
4. Bonneterre J, Spielmann M, Guastalla JP, Marty M, Viens P, Chollet P, Roche H, Fumoleau P, Mauriac L, Bourgeois H, Namer M, Bergerat JP, Misset JL, Trandafir L and Mahjoubi M: Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 35: 1431-1439, 1999. (Pubitemid 29454643)
5. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Østenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H and Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999. (Pubitemid 29359178)
6. Alexopoulos CG, Rigatos G, Efremidis AP, Papacharalambous A, Alexopoulos A, Vassilomanolakis M and Patila E: A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with poly chemotherapy. Hellenic Cooperative Interhospital Group in Oncology. Cancer Chemother Pharmacol 44: 253-258, 1999. (Pubitemid 29350182)
7. Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nistico C, Thorel MF, Marsella A, Caipino A, Giannarelli D, Terzoli E and Cognetti F: Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol 23: 132-139, 2000.
8. John PC: The platinum agents: a role in breast cancer treatment? Semin Oncol 28 (Suppl 3): 28-37, 2001.
9. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Rivera E and Hong WK: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995.
10. Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O and Le Cesne A: Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 10: 1457-1460, 1999. (Pubitemid 30017055)
11. Ogawa Y, Nishioka A, Inomata T, Tsuboi N, Hayase N, Fukumoto M, Yoshida S, Tochika N, Tanaka Y and Kumon M: Conservation treatment intensified with tamoxifen and CAF chemotherapy for subareolar breast cancers. Oncol Rep 5: 1337-1341, 1998. (Pubitemid 28474072)
12. Ogawa Y, Nishioka A, Inomata T, Yokota N, Sasaki T, Terashima M, Yoshida S, Tanaka Y and Tohchika N: Conservation treatment intensified with tamoxifen and CAF chemotherapy without axillary dissection for early breast cancer patients with clinically-negative axillary nodes. Oncol Rep 6: 801-805, 1999.
13. Ogawa Y, Nishioka A, Inomata T, Ohnishi T, Kariya S, Terashima M, Yoshida S, Tohchika N, Tanaka Y and Kumon M: Conservation treatment intensified with an anti-estrogen agent and CAF chemotherapy for stage I and II breast cancer. Oncol Rep 7: 479-484, 2000.
14. Terashima M, Ogawa Y, Kariya S, Inomata T, Nishioka A, Shimizu K, Yamanishi T, Tanaka Y, Tochika N and Yoshida S: Breast-conservation treatment for patients with ductal carcinoma in situ. Oncol Rep 7: 1247-1252, 2000.
15. Hamada N, Ogawa Y, Nishioka A, Kariya S, Terashima M, Yoshida S, Tanaka Y and Inomata T: An elderly patient with DCIS of the breast effectively treated with toremifene alone. Oncol Rep 9: 475-478, 2002.
16. Hamada N, Ogawa Y, Nishioka A, Kariya S, Terashima M, Yoshida S, Tochika N, Tanaka Y, Kumon M and Inomata T: Breast-conservation treatment for bilateral breast cancer in five Japanese women. Oncol Rep 9: 469-474, 2002.
17. Hata Y, Ogawa Y, Nishioka A, Inomata T and Yoshida S: Thin section CT in the prone position for detection of axillary lymph node metastases in breast cancer. Oncol Rep 5: 1403-1406, 1998. (Pubitemid 28474084)
18. Tsuboi N, Ogawa Y, Inomata T, Yoshida D, Yoshida S, Moriki T and Kumon M: Changes in the findings of dynamic MRI by preoperative CAF chemotherapy for patients with breast cancer of stage II and III. Oncol Rep 6: 727-732, 1999.
19. Nishioka A, Ogawa Y, Hamada N, Terashima M, Inomata T and Yoshida S: Analysis of radiation pneumonitis and radiation-induced lung fibrosis in breast cancer patients after breast conservation treatment. Oncol Rep 6: 513-517, 1999.
20. Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, Inomata T, Enzan H, Onishi S and Yoshida S: Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7: 1299-1304, 2000.
21. Takeuchi N, Fukumoto M, Nishioka A, Akagi N, Murata Y, Takeuchi S, Ogawa Y and Yoshida S: Scintigraphic prediction of response to chemotherapy in patients with breast cancer: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol 20: 53-58, 2002.
22. Hamada N, Ogawa Y, Saibara T, Murata Y, Kariya S, Nishioka A, Terashima M, Inomata T and Yoshida S: Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 17: 1119-1123, 2000.
23. Leonard RC, Rodger A and Dixon JM: ABC of breast diseases. Metastatic breast cancer. BMJ 309: 1501-1504, 1994.
24. 2in patients with metastatic breast cancer according to the status of anthracycline resistance. J Clin Oncol 19: 336-342, 2001.